Clinical trials: Huntington's Disease (HD)
Huntington Disease
Longitudinal Endpoint Assessment of Disease Burden in HD
LEAD-HD is intended to collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD participating in a 24-month longitudinal natural history study using remote technologies.
- Trial name
- LEAD-HD (NCT06475898)
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Huntington Study Group
Huntington's Disease, Chorea
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
- Trial name
- NCT07601516
- Testing
- Deutetrabenazine
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Huntington Disease
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm.
- Trial name
- INVEST-HD (NCT07326709)
- Testing
- Votoplam (blinded)
- Where
- 117 sites in United States, Argentina and 25 more
- Volunteers
- 770 people
- Sponsor
- Novartis Pharmaceuticals
Huntington Disease
Neurobiological Predictors of Huntington's Disease (PREDICT-HD)
The purpose of this trial is to study early brain and behavioral changes in people who have the gene expansion for Huntington's disease, but are currently healthy and have no symptoms.
- Trial name
- PREDICT-HD (NCT00051324)
- Where
- United States
- Volunteers
- 1,700 people
- Sponsor
- Jordan Schultz
Huntington Disease
Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease
Cellavita HD is a stem-cell therapy for Huntington's Disease. This is a first-in-human, non-randomized, phase I study in which participants with Huntington's Disease will receive three intravenous injections and will be followed…
- Trial name
- SAVE-DH (NCT02728115)
- Testing
- Cellavita HD Lower Dose, Cellavita HD Higher dose
- Where
- Brazil
- Volunteers
- 6 people
- Sponsor
- Azidus Brasil
Huntington's Disease
Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study
The purpose of this clinical trial is to extend the Pre-Crest study (Protocol # (NCT00592995) to further assess the long-term safety and tolerability of up to 30 grams daily creatine in individuals at-risk for Huntington's…
- Trial name
- Pre-CREST-X (NCT01411150)
- Testing
- Creatine Monohydrate
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Massachusetts General Hospital
Huntington's Disease
Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease
Huntington's Disease (HD) is an autosomal dominant disease manifested in a triad of cognitive, psychiatric, and motor signs and symptoms. HD is caused by a triplet repeat (CAG)expansion in the gene Huntingtin (HTT).
- Trial name
- ChANGE HD (NCT01860339)
- Where
- 6 sites in United States
- Volunteers
- 488 people, healthy volunteers welcome
- Sponsor
- Peggy C Nopoulos
Huntington Disease
Making HD Voices Heard
The Pilot Study, Making HD Voices Heard, will ask people living with HD to report what they experience and how they function.
- Trial name
- NCT05268029
- Where
- United States
- Volunteers
- 698 people
- Sponsor
- Huntington Study Group
Huntington Disease, Healthy
Digital Measures for Clinical Trial Endpoints in Huntington's Disease
MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons.
- Trial name
- MEND-HD (NCT07010705)
- Testing
- ActiGraph LEAP, Axivity AX6
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Parkinson Disease, Huntington Disease
Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.
The underlying goal of this study is to assess [123I]MNI-420 SPECT imaging as a tool to detect A2aR density in the brain of PD and HD research participants to be compared with similarly aged healthy subjects.
- Trial name
- MNI-420 (NCT00970229)
- Testing
- [123I]MNI-420
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Huntington's Disease
Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease
This study will examine whether lithium carbonate, given alone or with divalproex, increases the amount of brain-derived neurotrophic factor (BDNF) in the spinal fluid of patients with Huntington's disease (HD), a hereditary…
- Trial name
- NCT00095355
- Testing
- Lithium, Divalproex
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Huntington Disease
Creatine Safety and Tolerability in Premanifest HD: PRECREST
PRECREST is a two phase protocol for Huntington's disease in which 60 premanifest and at-risk subjects will first be randomized into a double blind placebo controlled dose titration study bringing them to 30 grams daily or their…
- Trial name
- PRECREST (NCT00592995)
- Testing
- Creatine monohydrate
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Massachusetts General Hospital
Huntington's Disease
Deep Brain Stimulation of the Globus Pallidus in Huntington's Disease
This is a single centre, controlled phase I study, which evaluates safety and efficacy of stimulation of lower caudal two contacts (GPI) vs. upper cranial two contacts (GPE) in Huntington´s disease (HD).
- Trial name
- NCT00902889
- Testing
- Stimulation
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Early Manifest Huntington Disease
A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be…
- Trial name
- VIBRANT-HD (NCT05111249)
- Testing
- Branaplam
- Where
- 12 sites in Canada, France and 3 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Huntington's Disease (HD)
Social Cognition Training in Individuals With Huntington's Disease
Individuals with Huntington's Disease have impaired social cognition, which is the domain of cognition that allows individuals to understand others' perspectives so that they can navigate interpersonal actions successfully (e.g.…
- Trial name
- NCT06828471
- Testing
- Social Cognition Training
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rush University Medical Center
Huntington Disease
Move to Improve: Telehealth Exercise to Music for HD
The purpose of this study is to determine if a movement to music exercise program delivered via telehealth is feasible and safe for individuals with neurodegenerative disease and their caregivers (Aim 1).
- Trial name
- MtI (NCT05270681)
- Testing
- Movement to Music
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Huntington Disease, Huntington's Disease
REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN)
This is a multi-centre, multi-national, prospective, observational study of Huntington's disease (HD) with a control group of volunteers to: obtain natural history data on many HD mutation carriers and individuals who are part of…
- Trial name
- REGISTRY (NCT01590589)
- Where
- 140 sites in Austria, Belgium and 15 more
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- European Huntington's Disease Network
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's…
- Conditions
- Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
- Trial name
- NCT05822908
- Testing
- VO659
- Where
- 14 sites in Denmark, France and 4 more
- Volunteers
- 68 people
- Sponsor
- Vico Therapeutics B. V.
Huntington's Disease
Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD
This study will evaluate the feasibility and acceptability of a clinic-based physical activity coaching intervention in people with pre-manifest and early stage Huntington's Disease (HD).
- Trial name
- NCT03306888
- Testing
- Physical Activity Coaching
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Teachers College, Columbia University
Huntington Disease
Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)
Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances.
- Trial name
- NCT00675077
- Testing
- Far Infrared Radiation
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- GAAD Medical Research Institute Inc.